Meeting
2013 ASCO Annual Meeting
Radiotherapy (RT) potentiation with weekly (q1w) or standard every 3 weeks (q3w) cisplatin chemotherapy (CT) for locally advanced head and neck squamous cell carcinoma (HNSCC).
Authors
Yann Molin
University of Lyon, centre Léon Bérard, Lyon, France
Yann Molin , Emilie Lavergne , Pascal Pommier , Severine Racadot , Xavier Montbarbon , Marc Poupart , Philippe Zrounba , Philippe Ceruse , Jerome Fayette
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6056)
DOI
10.1200/jco.2013.31.15_suppl.6056
Abstract #
6056
Poster Bd #
12D
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2022 ASCO Annual Meeting
NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma.
First Author: Christophe Le Tourneau
Poster
2018 ASCO Annual Meeting
Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.
First Author: Jared Weiss